Asher Bio
Lighting up only the immune cells that matter
Asher Biotherapeutics is a clinical-stage biotech company developing cis-targeted immunotherapies that selectively activate specific immune cell types to improve efficacy and reduce side effects. Their lead molecule, etakafusp alfa (AB248), is a cis-targeted IL-2 designed to specifically activate CD8+ effector T cells and is currently in Phase 1a/1b clinical trials. The company focuses on overcoming the limitations of conventional immunotherapies that act indiscriminately across multiple cell types.
Cis-targeted immunotherapies engage both an immunomodulatory receptor and a cell-type-specific target on the same immune cell, activating only the desired immune cell population.
oncology patients and clinical researchers
Background.
- Status
- launched
- Business model
- unknown
- Company
- Asher Biotherapeutics
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.